our vision<style=”text-align: justify;”>A world in which a simple blood draw will be sufficient for early cancer diagnosis, enabling physicians to select the best course of treatment, ultimately resulting in better patient outcomes.
Caring with Honesty – High Standards – Making a Difference Through Innovative Thinking – Teamwork – Partnership and Trust
We provide accurate tumor biopsy from a routine blood draw, truly suitable for low interval screening and for active surveillance and monitoring.
We rely on a unique biological principle and evolving science to build and validate highly sensitive and specific diagnostic tests.
Our approach is based on the detection of fundamental drivers of cancer (e.g. metabolic switch) and exosomes as early sentinels of tumor occurrence.
Our tests are simple, reliable, and cost-effective; we offer scalable and familiar test formats and provide them as open platform solutions.
Current investors are: Lonza, BioBalt Holding, BioFund, FinBiotech Srl, and Black Swan Trade Ltd.